2 Minutes with Joey - PFE Stock News

Epizódy

• PFE Today - Jul 19: Mixed Results for Cancer Drug 19.07.2026 1min

  Hey there! It’s Joey here, your friendly investor buddy, breaking down today’s stock moves. Today, we’re talking about Pfizer, and it was a bit of a red day for them, down just a smidge, like 0.36%. So, here’s the scoop. Pfizer's stock kinda hung around, not making any big waves. The volume was steady, but there wasn't much excitement. They dropped some mixed results related to a cancer drug they’re working on with Seagen, and that seemed to weigh on the stock a bit. People weren’t thrilled about the news, and when that happens, you know how it goes—some folks hit the sell button fast. Now, why the mixed results? Well, they released some data that didn’t fully meet the expectations some investors had. It’s a bummer when you’re hoping for a big win, and instead, it feels like a slow bleed. Plus, there’s chatter about Pfizer being a solid pick for those looking for cheap income stocks, but honestly, that didn’t seem to pump up the stock today. On the horizon, it looks like Pfizer is still getting some love for being a player in the AI healthcare space. There’s buzz about them leading a few AI healthcare names worth checking out, so that’s something to keep an eye on.Alright, that’s the lowdown on Pfizer today. Just remember, this is all for fun and info—no financial advice here. Catch you later!
• PFE Today - Jul 18: Mixed News, Slight Drop 18.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, breaking down the day for you. Today we’re talking about Pfizer, and it was a bit of a red day for them, down just a smidge. So, here’s the scoop. PFE dropped about 0.36%. Not a huge hit, but enough to make you raise an eyebrow. Trading was pretty active too, with a good chunk of shares changing hands, but it still felt like a slow bleed throughout the day. Now, why’d this happen? Well, the big news was mixed results from a cancer drug they’re working on with Seagen. When news like that hits, investors can get a little jittery, and it looks like some folks decided to hit the sell button. Plus, there’s chatter about Pfizer’s pipeline not being super exciting right now. Insiders aren’t really buying into the stock at this price either, which can make other investors a bit cautious. It’s like when your friends aren’t into a movie, you start questioning if you should go see it too, ya know? There’s also this ongoing talk about whether PFE is fairly priced or if it’s time to buy the dip. But honestly, with all the mixed signals out there, it’s tough to get a clear read on what’s gonna happen next. One quick thing to keep in mind: Pfizer is still holding support levels, so they’re not totally out of the game. They’re just waiting for something fresh to kick them back into gear. So, that’s the lowdown on Pfizer today. Just remember, I’m here to share info and keep it light, not to give financial advice. Keep doing your own research and stay curious! Catch you later!
• PFE Today - Jul 17: FDA Approval Hype Fades 17.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what happened with Pfizer today. So, let’s talk about PFE – it was a bit of a mixed bag today, but overall, it ended up in the green, gaining about 0.84%. Not a huge jump, but hey, at least it wasn't a total disaster, right?Now, here’s the scoop: there was some buzz around Pfizer getting a new FDA approval for a bladder cancer treatment, which had folks thinking maybe the stock was undervalued by around 16%. That sounds cool and all, but it seems like that hype didn’t really stick. Instead, investors were still feeling the sting from some disappointing news about a lung cancer trial. I mean, that can definitely overshadow any good vibes from the bladder cancer news. People were hitting the sell button fast, which kind of overshadowed the positive FDA approval talk.So, what’s the real deal? Analysts are saying that while the bladder cancer approval is a win, the overall pipeline for Pfizer has some risks. So, it’s like they’re walking a tightrope right now. Plus, there’s chatter about how the stock is trading below its 50-day and 200-day moving averages, and that’s got some folks debating whether to buy the dip or just cut their losses. It’s a little chaotic, to be honest.Oh, and just a quick note: insiders haven’t been buying up Pfizer stock at this price. Some folks think that’s actually a good sign, but it’s still a bit of a head-scratcher. It’s like, if they’re not buying, should we be worried? Or is it just a wait-and-see game? To wrap it up, Pfizer had a small gain today, but the excitement over the FDA approval didn’t quite hold up against the lung cancer trial disappointment. It’s a wild ride over there, and who knows what tomorrow will bring! Just remember, this is all for your info and entertainment, not financial advice. Catch you later!
• PFE Today - Jul 16: Mixed Results Impact Stock 16.07.2026 1min

  Hey there! It's Joey, your friendly longtime investor, here to break down what happened with Pfizer today. So, PFE had a green day, up about 1.69%. Not too shabby, right?But here’s the scoop: the stock was reacting to some mixed news. There were these topline results for a cancer drug developed with Seagen, and honestly, the info was all over the place. Some folks were excited, but others were scratching their heads. That uncertainty always gets people a bit jittery. On top of that, there’s a new patent claim hitting Pfizer after they raked in a whopping $96 billion from COVID vaccine sales. Yeah, that one stung a bit. It’s like, just when you think they’re cruising, bam! Another legal thing pops up. And let’s not forget, some analysts are saying the stock is looking fully priced after a 21% slump recently. So, there’s that too. Now, shifting gears a bit, there’s some promising news about Pfizer’s Lyme disease vaccine, which showed a solid 70% efficacy. That’s pretty cool and could be a game-changer if it gets the green light. So, to wrap it up, Pfizer had a bit of a bumpy ride today, but they’re still hanging in there with some interesting developments on the horizon. Just remember, I’m here to share info and keep it real, not to give financial advice. Catch you later!
• PFE Today - Jul 15: Bearishness Sparks Conversations 15.07.2026 1min

  Hey there! It’s Joey, your friendly longtime investor, breaking down the stock scene for you. Today, we’re talking about Pfizer, and it was a green day for them—up about 1.36%. Not a massive jump, but hey, we’ll take what we can get, right?So, what happened? Well, Pfizer managed to bounce back a bit today after a rough patch. After taking a hit recently, the stock saw some nice movement, but let’s be real, it’s still not back to where it wants to be. Volume was pretty low compared to usual, which tells me not a ton of action was happening. Now, why did this happen? There’s been a lot of chatter about bearish sentiments surrounding Pfizer and even Gilead Sciences, with some folks thinking this might be a contrarian opportunity. Basically, some investors are looking at the current dip and thinking, "Hey, maybe this is a chance to buy low." But others are still feeling the sting from Pfizer’s earlier 21% slump, making them cautious. Plus, there's buzz about Pfizer having the highest-yielding dividend in the S&P 500, which can be a double-edged sword—great for income, but it raises questions about sustainability. Oh, and there was some talk about a competitor, BioCryst Pharmaceuticals, having a rough day, which might’ve helped Pfizer look a little better in comparison. Sometimes it’s just about how you stack up against the competition, right?One thing worth keeping an eye on? The ongoing discussions about Pfizer’s dividend. Investors are definitely paying attention to how that plays out, especially with all the recent ups and downs.So, that’s the scoop on Pfizer today! It’s a bit of a mixed bag, but at least it’s not a total disaster. Remember, this is just for your info and entertainment—no financial advice here, folks! Catch you later!
• PFE Today - Jul 14: Drug Pricing Deals Impacting Pfizer 14.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Pfizer today. So, PFE had a red day, dropping about 0.8%. Ouch, right?Let’s get into it. Today was a bit rough for Pfizer. The stock got hit as news rolled in about drug pricing deals from Donald Trump that are shaking things up for big pharma. Investors were clearly feeling the weight of that news. Plus, there was a lot of chatter about some disappointing results from a lung cancer trial. That overshadowed Pfizer’s win with Ibrance, which is supposed to be a big deal. So yeah, it seems like people were hitting the sell button pretty fast.Now, why all the fuss? Well, it looks like these drug pricing deals could mean tighter profit margins for companies like Pfizer. The market's not really loving that, especially when you throw in a couple of price target cuts from big firms. BMO just slashed their target to $30 from $34, and Guggenheim did something similar, dropping it to $35. That’s not great for investor confidence. And when you mix that with the disappointment from the lung cancer trial, it’s no wonder folks are feeling skittish.One thing worth mentioning is that Pfizer did get FDA approval for something recently, but the market’s reaction was pretty muted. It’s like, “Yeah, cool, but what have you done for me lately?” That kind of vibe can really affect how stocks move, and today was a clear example of that.So, to wrap it all up: Pfizer’s facing some headwinds with drug pricing changes and trial results that didn’t quite hit the mark. It’s a tough spot, but that’s just how investing goes sometimes. Remember, this is just for fun and info, not financial advice. Catch you later!
• PFE Today - Jul 13: Price Target Cuts Hit Hard 13.07.2026 1min

  Hey there! It's Joey, your friendly investor buddy, breaking down what went down today with Pfizer. So, PFE had a bit of a green day, up about 1.82%. Not too shabby, right?But hold on, it wasn’t all sunshine and rainbows. The stock kinda had a rough ride earlier in the week. Today’s uptick was like a small bounce back after some recent price target cuts from analysts. Guggenheim lowered its target to $35, and BMO Capital followed suit, dropping theirs to $30. That’s never a fun thing to hear as a shareholder. People were probably feeling a bit jittery about it.Now, let’s talk about the why behind today’s action. Despite those price cuts, Pfizer scored a big win with FDA approval for its Lyme disease vaccine, showing a promising 70% efficacy. That’s incredible news, but it seems like Wall Street wasn’t super excited about it. The reaction was kinda muted, like when you tell your friends about a cool new game and they’re just like, “Yeah, cool.” It’s a bummer when good news doesn’t translate to excitement on the stock side, right? And get this—there's a lot going on in the healthcare space right now. While Pfizer's vaccine news is solid, the market's still buzzing about other big players making moves, like Novo Nordisk launching a subscription model for Wegovy. Everyone's trying to figure out how these shifts impact the whole scene.So, yeah, that’s the lowdown on Pfizer today. Always a mix of wins and losses in the stock game. Just remember, this is all info for you to chew on, not financial advice or anything. Keep your head up, and I’ll catch you later!
• PFE Today - Jul 12: Lung Cancer Trial Disappointment 12.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what happened today with Pfizer. So, PFE had a red day, dropping about a third of a percent. Nothing too crazy, but still not great.What went down? Well, it looks like folks are still feeling the sting from some disappointing news about a lung cancer trial. Yeah, that one stung. People were really hoping for a win there, but it didn’t pan out. On the flip side, there was some good news too—Pfizer got a thumbs up from the FDA for a new bladder cancer treatment. But the lung cancer news overshadowed that, and you know how it goes; bad news travels faster.So why the drop? Investors are reacting to the lung cancer trial disappointment. It seems like that’s weighing heavy on everyone’s minds. Even though they had a win with the bladder cancer regimen, the market's mood was already set. When people see a setback like that, they tend to hit the sell button fast. It’s like a chain reaction, you know?And just to throw a little extra info your way, Pfizer also had news about their Lyme disease vaccine showing some solid efficacy. But honestly, it feels like that news got lost in the shuffle today. One thing worth knowing is that Pfizer’s got more in the pipeline, and they’re still pushing forward with their research. So, while today wasn’t a banner day, there's still stuff happening behind the scenes.Alright, that’s a wrap for today’s recap! Hope that helped clear things up. Remember, I’m just here to share the info, not to give any financial advice. Catch you later!
• PFE Today - Jul 11: Pfizer's Slow Day 11.07.2026 1min

  Hey, what’s up? It’s Joey here, your friendly neighborhood investor, breaking down the day’s action. Today, we’re talking about Pfizer. It was a bit of a rough ride, closing down just a smidge—like, down 0.33%. Yeah, that one stung a little.So, what went down? Well, the stock kinda just sat there, barely moving. It wasn’t a huge day for trading, with volume coming in lower than usual. Just 27 million shares changed hands, which is less than half of what we typically see. A slow bleed for sure.Now, let’s get into the why behind this action. There’s been a lot of chatter about Pfizer lately. Some folks are saying it’s a solid defensive pick in this market. But then, you’ve got Jim Cramer throwing some shade, saying he can’t see where the growth is coming from. Ouch! That’s a tough spot to be in, especially when people are looking for excitement. On the flip side, some articles are highlighting Pfizer’s potential in the AI healthcare space, saying it’s one of three picks worth a closer look. So, it’s like a mixed bag of opinions out there.And here’s something interesting: there’s chatter about a post-pandemic turnaround happening for Pfizer. They’re seen as undervalued right now, which might mean some upside in the future if they play their cards right. But until then, it’s just a lot of waiting and seeing.Anyway, that’s the scoop on Pfizer today. If you’re in it for the long haul, hang tight and keep an eye on the news. Remember, I’m just here to keep you informed and entertained, not to give financial advice. Catch you later!
• PFE Today - Jul 10: Mixed Signals in Pharma 10.07.2026 1min

  Hey there! It’s Joey here, your go-to guy for breaking down the stock scene. I’ve been at this investing game for years, and today we’re talking about Pfizer. So, was it a green or red day? Well, it was a slight red day, down just a smidge—like, 0.08%. Now, what happened? The stock kinda just floated around. It didn’t really get smoked, but it also didn’t pop off. Volume was way lower than usual, which means not a lot of folks were trading it today. It's like everyone was just chillin’, not making any big moves. So, why the slow bleed? Well, there’s some chatter about how Pfizer’s growth isn't looking super exciting right now. An article compared it to McDonald’s, saying one has real growth potential while the other is just kinda hanging out, paying dividends and waiting for something to happen. That's a tough spot to be in, ya know? Investors want to see some action, not just a wait-and-see game. Plus, there was some buzz about AstraZeneca crashing a bit, which dragged Pfizer along with it. When one big player stumbles, it can send shockwaves through the whole sector. People start getting nervous, and that’s never good for the vibe.And hey, here’s something to keep an eye on: there’s been talk about AI in healthcare, and Pfizer got a mention as one of the stocks worth a look in that space. So, while it’s not exactly a rocket ship right now, there’s potential for some interesting developments down the line. Alright, that’s a quick scoop on Pfizer today. Just remember, this is all for fun and info, not financial advice. Catch you later!
• PFE Today - Jul 09: AstraZeneca's Crash Boosts Rivals 09.07.2026 1min

  Hey there! It’s Joey, your friendly investor buddy. Let’s break down what went down with Pfizer today. So, PFE had a pretty chill day, closing up just a little, like 0.54%. Not exactly fireworks, but hey, it’s something, right?So, here’s the scoop. Pfizer didn’t have a huge move on its own, but it kinda rode the coattails of AstraZeneca’s rough day. AstraZeneca took a dive, crashing about 8%. That’s a big deal! When one of your rivals gets smoked like that, it can give others a little boost. Pfizer and a couple of other competitors saw some green as folks shifted their focus. It’s like the old saying goes—when one ship sinks, others might float a bit higher.Now, why did AstraZeneca crash? Well, it looks like they had some bad news that spooked investors. Not exactly the best headlines for them, and that ripple effect gave Pfizer a little lift. But let’s be real, nobody's really popping champagne over a 0.54% gain. It’s more like a gentle nudge forward rather than a major win.Oh, and here’s something interesting on the horizon. Pfizer's Lyme disease vaccine is showing some solid promise, with reports saying it has 70% efficacy. That’s some good news, especially considering the whole vaccine game is still a hot topic. It might not be a game-changer right away, but it’s definitely something to keep an eye on.So, to wrap it up, Pfizer had a bit of a quiet day, but it got a slight lift thanks to AstraZeneca’s misfortune. Not the most exciting movement, but hey, every little bit counts, right? Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!
• PFE Today - Jul 09: AstraZeneca Drama Boosts Rivals 09.07.2026 1min

  Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Pfizer today. So, we’re talking about PFE, and it had a green day, up just a bit by about half a percent. Not a huge jump, but hey, green is good!Now, here’s the scoop. Pfizer started the day kinda slow but picked up some steam after some news about AstraZeneca. They took a hit, dropping about 8%. That news kinda shook things up in the market, and investors seemed to think, “Hey, if AstraZeneca’s struggling, maybe there’s a chance for Pfizer and some of the other big pharma players to step in.” So, people started hitting that buy button for Pfizer, and that helped it stay in the green.But let’s talk about the bigger picture. A few things are swirling around Pfizer lately. There’s chatter about their Lyme disease vaccine showing some solid numbers—70% efficacy, which is pretty impressive. That’s the kind of news that can get people excited. But then there’s also the other side of the coin. Some folks are saying that Pfizer's dividend is looking a bit risky right now. That’s a mixed bag, for sure. And just to throw a little more drama into the mix, there’s a story about a former Pfizer building crumbling, which is kinda wild. I mean, that’s not exactly the best look for a company, right? Oh, and just to keep you in the loop, there’s been some talk about what to look for before buying into pharma stocks. So, if you’re thinking about it, just keep your eyes peeled. Alright, that’s the lowdown on Pfizer today! It’s always a rollercoaster in the stock world. Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later, and happy investing!
• PFE Today - Jul 08: Market Gains, Pfizer Sinks 08.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while now, and today we’re talking about Pfizer, ticker PFE. So, was it a green day or a red day? Well, it was a bit of a bummer—Pfizer dipped by a tiny bit, down 0.08%. Yeah, that one stung.So, what happened? The stock got smoked today, even while the overall market was doing pretty well. It’s like Pfizer just decided to take a nap while everyone else was partying. The volume was lower than usual too, which is kind of a sign that people weren’t super excited about jumping in. Now, why did this happen? Well, there were a couple of things floating around. First off, there’s some chatter about a former Pfizer building falling apart. Not exactly a great look, right? It’s like when your old high school has a leaky roof and you’re just like, “Yikes, maybe it’s time to renovate.” On top of that, even with some buzz around FDA approvals for their drugs, it seems like investors are still a bit cautious. They might be waiting to see if those approvals actually translate into cash flow. A few articles mentioned that Pfizer is still a solid player in the healthcare space, but it feels like folks are just holding their breath for now. Looking ahead, one thing to keep an eye on is that some analysts think Pfizer might be undervalued after that new FDA approval for IBRANCE. So, there’s potential there, but who knows when that’ll kick in? That’s the scoop for today! Pfizer’s got some hurdles to jump over, but it’s still in the game. Just remember, I’m here to keep you informed and entertained, not to give financial advice. Catch you later!
• PFE Today - Jul 07: HSBC Downgrades Pfizer Stock 07.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor. I’ve been in the game for a while, and today I’m breaking down Pfizer. So, PFE had a bit of a mixed bag today, closing down about 1.6%. Now, let’s talk about what went down. The stock got hit hard after HSBC decided to downgrade it. Yeah, that one stung. They basically said there’s not much happening in the near term for Pfizer that would make it a must-have. Ouch. On top of that, while the overall market was gaining, PFE was just kinda sinking. It’s like when you’re at a party, and everyone’s dancing, but you’re stuck in the corner. Not a great look.So, why did HSBC pull the trigger on this downgrade? Well, they pointed out that Pfizer's been lacking some solid catalysts lately. You know, those game-changing announcements or products that get investors hyped. They’re also weighing the competition against other big names like AstraZeneca. So, when you stack it all up, there’s a lot of uncertainty hanging over Pfizer right now, and people don’t like that. Oh, and here’s a little silver lining: Pfizer did announce some promising results for their Lyme disease vaccine, showing 70% efficacy. That’s great news! But with all the noise from the downgrade, it’s not doing much to lift the stock today.To wrap it up, Pfizer's had a rough one. Downgraded, not a lot of excitement, and it’s just not the hot topic right now. But hey, investing is a marathon, not a sprint. Keep your cool, and remember, this is just for fun and info, not financial advice. Catch you later!
• PFE Today - Jul 06: HSBC Downgrades Pfizer Stock 06.07.2026 1min

  Hey there! It's Joey here, your friendly neighborhood investor, breaking down today’s stock action. Today, we’re chatting about Pfizer, and it was a red day for them—down about 2.6%. Ouch.So, what happened? Well, Pfizer got smoked today, and a big part of that was HSBC downgrading their stock rating. They basically said there’s a lack of near-term catalysts to get the stock moving in a positive direction. That kind of news can make investors a bit jittery, and it felt like people were hitting the sell button fast.Now, why did HSBC feel this way? They pointed out that there’s not much in the pipeline that’s gonna pump up Pfizer’s stock anytime soon. I mean, if you’re looking for excitement in the stock market, a company without fresh news or breakthroughs isn’t exactly gonna get you hyped, right? It’s like waiting for a sequel to a movie that never comes out. On a different note, there’s some chatter around Pfizer being a top dividend stock, especially with hedge funds eyeing it due to an FDA milestone for Ibrance. That’s their breast cancer treatment, and it’s got some folks thinking it might still be a solid long-term hold. So, while today wasn’t great, there’s a glimmer of hope on the horizon if you’re into dividends.Anyway, that’s the scoop on Pfizer today. Just remember, I’m here to give you the info, not financial advice. Keep it chill, and I’ll catch you later!